| ORIGINAL ARTICLE |
|
| Ahead of Print |
|
|
Immunohistochemical evaluation of p16 and p53 in oral and oropharyngeal squamous cell carcinoma with special regard to human papillomavirus status
Urvashi Ghosh1, Rajashree Tripathy1, Anasuya Lenka1, Jyotirmayee Turuk2, Debahuti Mohapatra1
1 Department of Pathology, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, Indi, India
2 Indian Council of Medical Research, Regional Medical Research Centre, Bhubaneswar, Odisha, India
Correspondence Address:
Anasuya Lenka,
Department of Pathology, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha
India
 Source of Support: None, Conflict of Interest: None DOI: 10.4103/jmau.jmau_84_21
|
|
|
Background: Incidence of human papillomavirus (HPV)-associated oral and oropharyngeal squamous cell carcinomas (OSCC and OPSCC) is on a rising trend globally and has specific therapeutic implications. HPV-related tumors have a distinct pathogenetic mechanism targeting p16 and p53 both. However, there are limited studies evaluating p16 and p53 expression in combination. Aim: The aim of the study is to evaluate p16 and p53 immunohistochemical expression pattern in OSCC and OPSCC, with special reference to HPV association. Study Design: This was a hospital-based prospective study done over 22 months (September 2018 to June 2020), including a total of 54 cases of OSCC and OPSCC. They were subjected to clinicopathological evaluation, p16 and p53 immunohistochemistry, and DNA polymerase chain reaction testing for testing of HPV association, followed by analysis of data by statistical methods. Results: Out of 54, 43 cases were OSCC and 11 cases were OPSCC. A total of nine cases were HPV positive. HPV association was found to be significant with tonsil as primary site, age range between 40 and 60 years, and absence of tobacco or alcohol habit. Presence of HPV infection was also significantly associated with p16 overexpression, in combination with p53 negativity. The findings indicate that p16 overexpression combined with a negative p53 expression can be used for HPV detection and the former alone may be used as diagnostic marker in OPSCC only. Conclusion: HPV-associated OSCC and OPSCC are a unique subset of cancers, and using combination of molecular biomarkers could help in diagnosis and prognosis.
|
|
|
|
|
|
|
Search Pubmed for